Please explain why it has NO relevancy. I understand it doesn't satisfy your preferences, but to dismiss historical pharma business partnerships and what may or may not be in the future for NNVC as TOTALLY IRRELEVANT seems a bit hyperbolic. Please educate me on that logic if you would be so kind.
I was wondering why they avoided talking about their revenues in their fluff PR, so I went and looked up their SEC filing.
Now I get the song and dance. They are a cash burning machine.
Business model: Burn cash, dilute stock, issue fluff PR about how great everything is and the magic snake oil is coming along nicely. Complain that mean people and short sellers are to blame for disastrous management.
Gliknik and Pfizer for GL-2045, $25 million upfront plus benchmark payments. Drug was IND-enabled and not yet in trials. www.prnewswire.com/news-releases/gliknik-enters-into-licensing-agreement-with-pfizer-for-drug-candidate-targeting-autoimmune-diseases-225786531.html
Interesting. So, you know what management has in place and what it doesn't? Again interesting.
Market Data 
Markets 
AI
